Scarica l'app Stockscreener
2.45
3.66%
-0.093
Dopo l'orario di chiusura:
2.52
0.07
+2.86%
Precedente Chiudi:
$2.543
Aprire:
$2.55
Volume 24 ore:
54,954
Relative Volume:
0.23
Capitalizzazione di mercato:
$6.64M
Reddito:
$202.00K
Utile/perdita netta:
$-28.96M
Rapporto P/E:
-4.0833
EPS:
-0.6
Flusso di cassa netto:
$-21.85M
1 W Prestazione:
-9.26%
1M Prestazione:
-22.22%
6M Prestazione:
+1,816%
1 anno Prestazione:
+580.74%
Intervallo 1D:
$2.40
$2.57
Intervallo di 1 settimana:
$2.40
$2.68
Portata 52W:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
Nome
AIM ImmunoTech Inc
Settore
Industria
Telefono
352 448 7797
Indirizzo
2117 SW Highway 484, Ocala, FL
Confronta AIM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
2.45 | 6.89M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders - Quantisnow
AIM ImmunoTech releases CEO Corner segment - MSN
AIM ImmunoTech Releases CEO Corner Segment, Discusses Recent Progress with Ampligen - AInvest
AIM ImmunoTech Announces CEO Corner Segment Release - AInvest
AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewswire
Biotech AIM ImmunoTech's CEO Details Progress of Promising Pancreatic Cancer Drug Ampligen in Latest Update - Stock Titan
AIM ImmunoTech's Oncology Gambit: Can Pancreatic Cancer Breakthroughs and Financial Stability Fuel a Biotech Comeback? - AInvest
AIM ImmunoTech reports Q2 EPS ($3.68) vs ($3.00) last year - MSN
AIM ImmunoTech Reports Q2 Losses Amid Ongoing Trials, Revenue Down to $25k. - AInvest
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Promising Pancreatic Cancer Treatment: AIM ImmunoTech's Ampligen Shows Strong Safety Data in Phase 2 - Stock Titan
Webull Corporation shares rise 1.49% premarket after AIM ImmunoTech and Moleculin Biotech to present at Webull Financial Corporate Connect Webinar Series. - AInvest
AIM ImmunoTech Reports Increased Losses Amid Ongoing Trials - TipRanks
AIM ImmunoTech to present at Webull Financial Corporate Connect webinar. - AInvest
AIM ImmunoTech CEO to Share Company Updates at Webull's Biotech Investment Series - Stock Titan
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire
AIM ImmunoTech Presents at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. - AInvest
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - 富途牛牛
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Pr - GuruFocus
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - The Manila Times
AIM ImmunoTech (AIM) Advances Clinical Trials and Strengthens Financial Position - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval | AIM Stock News - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: AIM's Ampligen-Imfinzi Combo Shows Positive Survival Data - Stock Titan
AIM ImmunoTech Surges Amid Key Developments, Raises $8 Million in Public Offering - AInvest
AIM ImmunoTech Closes $8 Million Public Offering - The Globe and Mail
Latest News - Asia Food Journal
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech closes public offering, raises $8 mln. - AInvest
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - MSN
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering - AInvest
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Stock Dives 50% After Priced Public Offering - AInvest
Why Is AIM ImmunoTech Stock (AIM) Down 50% Today? - TipRanks
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
AIM ImmunoTech Inc Azioni (AIM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):